Ä«Æä½ÃŸºó ½ÃÀå : ÀûÀÀÁõº°, °­µµº°, ¾àÁ¦ À¯Çüº°, ¿¬·ÉÃþº°, À¯Åë ä³Îº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Capecitabine Market, By Indication, By Strength, By Drug Type, By Age Group, By Distribution Channel, By End User, By Geography
»óǰÄÚµå : 1812460
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,376,000
Unprintable PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,919,000
PDF & Excel (Multi User License - Up to 7 Users) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ÃÖ´ë 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,171,000
PDF & Excel (Corporate User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ä«Æä½ÃŸºó ½ÃÀåÀº 2025³â¿¡ 4¾ï 9,230¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â±îÁö´Â 7¾ï 6,010¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 6.4%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ý¾× 4¾ï 9,230¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR : 6.40% 2032³â ±Ý¾× ¿¹Ãø 7¾ï 6,010¸¸ ´Þ·¯

¼¼°èÀÇ Ä«Æä½ÃŸºó ½ÃÀåÀº 5-Ç÷ç¿À·Î¿ì¶ó½Ç(5-FU)ÀÇ ÇÁ·Îµå·¯±× ¿ªÇÒÀ» ÇÏ´Â °æ±¸¿ë Ç÷ç¿À·ÎÇǸ®¹ÌµòÄ«¸£¹Ù¸ÞÀÌÆ®(fluoropyrimidine carbamate)¸¦ Áß½ÉÀ¸·Î ÇÑ ¾Ï ºÐ¾ß ÀǾàǰÀÇ Áß¿äÇÑ ½ÃÀåÀÔ´Ï´Ù.

Ä«Æä½ÃŸºóÀº µ¶Æ¯ÇÑ Á¾¾ç ¼±ÅÃÀû Ȱ¼ºÈ­ ±âÀü°ú Á¤¸ÆÁÖ»ç ´ëºñ °³¼±µÈ ȯÀÚ ¼øÀÀµµ¸¦ ¹ÙÅÁÀ¸·Î ´ëÀå¾Ï, À¯¹æ¾Ï, À§¾Ï µî ¾Ï Ä¡·á ÇÁ·ÎÅäÄÝÀÇ ÇÙ½É Ä¡·áÁ¦·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¾à¹°ÀÇ Çõ½ÅÀûÀÎ ¼³°è´Â 3´Ü°è È¿¼Ò ij½ºÄÉÀ̵带 ÅëÇØ Á¾¾ç Á¶Á÷ ³»¿¡¼­ Ȱ¼º ´ë»ç»ê¹°·Î ¿ì¼±ÀûÀ¸·Î ÀüȯµÇ¾î Àü½Å µ¶¼ºÀ» ÃÖ¼ÒÈ­Çϸ鼭 Ä¡·á È¿°ú¸¦ Å©°Ô ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù.

¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ¸ÂÃãÇü ÀÇ·á¿Í ȯÀÚ Áß½ÉÀÇ Ä¡·á Á¢±Ù¹ýÀÌ Á¡Á¡ ´õ ¿ì¼±½ÃµÇ´Â °¡¿îµ¥, Ä«Æä½ÃŸºóÀÇ °æ±¸ Åõ¿© °æ·Î´Â ÆíÀǼº, »îÀÇ Áú, ÀÇ·á ÀÚ¿ø ÃÖÀûÈ­ Ãø¸é¿¡¼­ Å« ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº ´Ù¾çÇÑ Á¦Çü, ¿ë·®, º´¿ë¿ä¹ý, ´Üµ¶¿ä¹ý ¹× ¼ö¼ú ÈÄ º¸Á¶¿ä¹ý ÇÁ·ÎÅäÄÝÀ» ¸ðµÎ Æ÷°ýÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è ¾Ï ¹ßº´·ü Áõ°¡, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¾Ï Ä¡·á Á¢±Ù¼º È®´ë, »õ·Î¿î º´¿ë Àü·«¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸·Î ÀÎÇØ Ä«Æä½ÃŸºó ½ÃÀåÀº Àü ¼¼°è ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ Á¾ÇÕÀûÀÎ ¾Ï Ä¡·á Àü·«ÀÇ ÇÙ½É ¿ä¼Ò·Î °è¼Ó ÁøÈ­Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°èÀÇ Ä«Æä½ÃŸºó ½ÃÀåÀº ¾Ï Ä¡·á¿¡¼­ Ä«Æä½ÃŸºóÀÇ Á߿伺 Áõ°¡¸¦ Áö¿øÇÏ´Â ¸î °¡Áö °­·ÂÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀο¡ ÀÇÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ù ¹øÂ° ¿äÀÎÀº ´ëÀå¾Ï°ú À¯¹æ¾ÏÀÌ ¼¼°è¿¡¼­ °¡Àå ¹ßº´·üÀÌ ³ôÀº µÎ °¡Áö ¾Ç¼º Á¾¾çÀ¸·Î È¿°úÀûÀÎ °æ±¸¿ë È­Çпä¹ý¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ´Â Àü ¼¼°è ¾Ï ¹ßº´·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. °æ±¸ Åõ¿©´Â º´¿ø ¹æ¹® Ƚ¼ö¸¦ ÁÙÀ̰í, »îÀÇ ÁúÀ» °³¼±Çϸç, ÀÇ·á ½Ã½ºÅÛÀÇ ºÎ´ãÀ» ÁÙÀ̱â À§ÇÔÀÔ´Ï´Ù.

¶ÇÇÑ ¾Ï¿¡ Ãë¾àÇÑ °í·ÉÀÚ Àα¸°¡ Áõ°¡Çϰí ÀÖ°í, Ä«Æä½ÃŸºóÀÇ °ü¸® °¡´ÉÇÑ µ¶¼º ÇÁ·ÎÆÄÀÏÀÌ ÁýÁßÀûÀÎ Á¤¸ÆÁÖ»ç ¿ä¹ýÀ» °ßµðÁö ¸øÇÏ´Â °í·É ȯÀڵ鿡°Ô ÀûÇÕÇÏ´Ù´Â Á¡ÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª Á¦³×¸¯ ÀǾàǰÀÇ µîÀåÀ¸·Î ºê·£µå ÀǾàǰÀÇ °¡°Ý ¾Ð·ÂÀÌ Å©°Ô ³·¾ÆÁö°í, Çõ½Å ±â¾÷ÀÇ ¸ÅÃâ ¼ºÀåÀÌ Á¦ÇÑµÉ ¼ö ÀÖ´Â µî ½ÃÀåÀº Å« ¾ïÁ¦¿äÀο¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù.

¼öÁ·ÁõÈıº, À§Àåµ¶¼º, ÀáÀçÀû ½Éµ¶¼º µî ½É°¢ÇÑ ºÎÀÛ¿ëÀº Ä¡·á Áß´ÜÀ¸·Î À̾îÁú ¼ö ÀÖÀ¸¸ç, ½ÃÀå ħÅõ¸¦ Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç¥ÀûÄ¡·áÁ¦, ¸é¿ªÄ¡·áÁ¦, »õ·Î¿î ¾à¹°Àü´Þ½Ã½ºÅÛÀÇ ÃâÇöÀº Ä«Æä½ÃŸºó°ú °°Àº ±âÁ¸ È­Çпä¹ýÁ¦¿¡ °æÀïÀû ¹®Á¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ÇÏÁö¸¸, ƯÈ÷ Ç¥ÀûÄ¡·áÁ¦³ª ¸é¿ªÁ¶ÀýÁ¦¿ÍÀÇ º´¿ë¿ä¹ý °³¹ßÀ» ÅëÇØ Ä¡·á È¿°ú¸¦ ³ôÀ̰í Ä¡·á ÀûÀÀÁõÀ» È®´ëÇÒ ¼ö ÀÖ´Â Å« ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. ÇÑÆí, ÇöÀç ÁøÇà ÁßÀÎ ¾à¸®À¯Àüü ÇÁ·ÎÆÄÀÏ¿¡ ±â¹ÝÇÑ °³Àκ° ¸ÂÃã Åõ¿© Àü·«¿¡ ´ëÇÑ ¿¬±¸´Â ÁøÈ­ÇÏ´Â Á¾¾çÇÐ »óȲ¿¡¼­ ½ÃÀå È®´ë¿Í ȯÀÚ ¿¹ÈÄ °³¼±ÀÇ ±æÀ» Á¦½ÃÇÒ °ÍÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ Ä«Æä½ÃŸºó ½ÃÀå, ÀûÀÀÁõº°, 2020-2032³â

Á¦5Àå ¼¼°èÀÇ Ä«Æä½ÃŸºó ½ÃÀå, °­µµº°, 2020-2032³â

Á¦6Àå ¼¼°èÀÇ Ä«Æä½ÃŸºó ½ÃÀå, ¾àÁ¦ À¯Çüº°, 2020-2032³â

Á¦7Àå ¼¼°èÀÇ Ä«Æä½ÃŸºó ½ÃÀå, ¿¬·ÉÃþº°, 2025-2032³â

Á¦8Àå ¼¼°èÀÇ Ä«Æä½ÃŸºó ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â

Á¦9Àå ¼¼°èÀÇ Ä«Æä½ÃŸºó ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020-2032³â

Á¦10Àå ¼¼°èÀÇ Ä«Æä½ÃŸºó ½ÃÀå, Áö¿ªº°, 2020-2032³â

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È

Á¦13Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Capecitabine Market is estimated to be valued at USD 492.3 Mn in 2025 and is expected to reach USD 760.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 492.3 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.40% 2032 Value Projection: USD 760.1 Mn

The global capecitabine market represents a critical segment within the oncology pharmaceutical landscape, centered around an oral fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU).

Capecitabine has established itself as a cornerstone therapeutic agent in cancer treatment protocols, particularly for colorectal, breast, and gastric cancers, owing to its unique tumor-selective activation mechanism and improved patient compliance compared to intravenous alternatives. The drug's innovative design allows for preferential conversion to its active metabolite within tumor tissues through a three-step enzymatic cascade, significantly enhancing therapeutic efficacy while minimizing systemic toxicity.

As healthcare systems worldwide increasingly prioritize personalized medicine and patient-centric treatment approaches, capecitabine's oral administration route offers substantial advantages in terms of convenience, quality of life, and healthcare resource optimization. The market encompasses various formulations, dosage strengths, and combination therapies, serving both monotherapy and adjuvant treatment protocols. With rising global cancer incidence rates, expanding access to oncology care in emerging markets, and continuous research into novel combination strategies, the capecitabine market continues to evolve as a vital component of comprehensive cancer care strategies across diverse healthcare settings worldwide.

Market Dynamics

The global capecitabine market is propelled by several compelling drivers that underscore its growing significance in oncology therapeutics. The primary driver stems from the escalating global cancer burden, with colorectal and breast cancers representing two of the most prevalent malignancies worldwide, creating sustained demand for effective oral chemotherapy options. The drug's superior patient compliance profile compared to intravenous chemotherapy regimens drives adoption, as oral administration reduces hospital visits, improves quality of life, and decreases healthcare system burden.

Additionally, the expanding geriatric population, which exhibits higher cancer susceptibility, fuels market growth as capecitabine's manageable toxicity profile makes it suitable for elderly patients who may not tolerate intensive intravenous therapies. However, the market faces significant restraints including the availability of generic versions that have substantially reduced pricing pressures on branded formulations, potentially limiting revenue growth for innovator companies.

Severe side effects such as hand-foot syndrome, gastrointestinal toxicity, and potential cardiotoxicity can lead to treatment discontinuation, restricting market penetration. Furthermore, the emergence of targeted therapies, immunotherapies, and novel drug delivery systems poses competitive challenges to traditional chemotherapy agents like capecitabine. Nevertheless, substantial opportunities exist through combination therapy development, particularly with targeted agents and immunomodulators, which can enhance therapeutic efficacy and expand treatment indications. Growing healthcare infrastructure in emerging markets presents untapped potential, while ongoing research into personalized dosing strategies based on pharmacogenomic profiles offers avenues for market expansion and improved patient outcomes in the evolving oncology landscape.

Key Features of the Study

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Capecitabine Market, By Indication, 2020-2032, (USD Mn)

5. Global Capecitabine Market, By Strength, 2020-2032, (USD Mn)

6. Global Capecitabine Market, By Drug Type, 2020-2032, (USD Mn)

7. Global Capecitabine Market, By Age Group, 2025-2032, (USD Mn)

8. Global Capecitabine Market, By Distribution Channel, 2020-2032, (USD Mn)

9. Global Capecitabine Market, By End User, 2020-2032, (USD Mn)

10. Global Capecitabine Market, By Region, 2020 - 2032, Value (USD Mn)

11. Competitive Landscape

12. Analyst Recommendations

13. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â